Clinical Trial Update: Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating NOX66 as monotherapy and with carboplatin in refractory solid tumors completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• NOX66

Snippet

Sponsor: Noxopharm Limited | Conditions: Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-06-02